Get the Stockscreener App
3.97
13.04%
-0.63
Artiva Biotherapeutics Inc stock is traded at $3.97, with a volume of 77,628.
It is down -13.04% in the last 24 hours and down -62.19% over the past month.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials.
See More
Previous Close:
$4.60
Open:
$4.58
24h Volume:
77,628
Relative Volume:
1.18
Market Cap:
$101.53M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-21.26%
1M Performance:
-62.19%
6M Performance:
-64.60%
1Y Performance:
+0.00%
1-Day Range:
$3.96
$4.63
1-Week Range:
$3.985
$5.325
52-Week Range:
$3.985
$17.31
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
Name
Artiva Biotherapeutics Inc
Sector
Industry
Phone
(858) 267-4467
Address
5505 MOREHOUSE DRIVE, SAN DIEGO
Compare ARTV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTV
Artiva Biotherapeutics Inc
|
3.98 | 101.53M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.05 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
714.60 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
648.00 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.24 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.44 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-13-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Initiated | Jefferies | Buy |
| Aug-13-24 | Initiated | Needham | Buy |
| Aug-13-24 | Initiated | TD Cowen | Buy |
| Aug-13-24 | Initiated | Wedbush | Outperform |
View All
Artiva Biotherapeutics Inc Stock (ARTV) Latest News
Artiva Leverages Unmodified NK Cells To Challenge CAR-T Paradigm - In Vivo
JPMorgan Chase & Co. Buys New Holdings in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Artiva Biotherapeutics appoints new director and committee members By Investing.com - Investing.com South Africa
Artiva Biotherapeutics expands board with industry veteran By Investing.com - Investing.com South Africa
Artiva Biotherapeutics expands board with industry veteran - MSN
Artiva Biotherapeutics appoints new director and committee members - Investing.com India
Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D. - GlobeNewswire
Former J&J Drug Development Chief Who Created Multi-Billion Dollar Therapies Joins Rising Biotech Board - StockTitan
Natural killer cells, a rising alternative to CAR-T cell therapy - Yahoo Finance
Brokerages Set Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Target Price at $21.00 - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Cantor Fitzgerald Predicts ARTV FY2025 Earnings - Defense World
Cantor Fitzgerald Weighs in on ARTV FY2025 Earnings - MarketBeat
Barclays PLC Buys Shares of 19,616 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics surges on trading debut - MSN
Artiva Biotherapeutics announces pricing of upsized $167M IPO - MSN
Aligos Therapeutics (NASDAQ:ALGS) & Artiva Biotherapeutics (NASDAQ:ARTV) Head to Head Contrast - Defense World
Artiva Biotherapeutics, Inc.'s Lock-Up Period To End on January 15th (NASDAQ:ARTV) - MarketBeat
Artiva Biotherapeutics, Inc.’s Lock-Up Period To Expire on January 15th (NASDAQ:ARTV) - Defense World
Geode Capital Management LLC Acquires Shares of 308,930 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat
Geode Capital Management LLC Makes New Investment in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Barclays PLC Makes New Investment in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
State Street Corp Invests $1.34 Million in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat
State Street Corp Acquires Shares of 86,559 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
What is HC Wainwright’s Estimate for ARTV FY2024 Earnings? - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $21.25 Average PT from Brokerages - Defense World
Research Analysts Issue Forecasts for ARTV FY2024 Earnings - MarketBeat
HC Wainwright & Co. Initiates Coverage of Artiva Biotherapeutics (ARTV) with Buy Recommendation - MSN
Artiva Biotherapeutics's SWOT analysis: NK cell therapy stock poised for growth - Investing.com India
Artiva Biotherapeutics’s SWOT analysis: NK cell therapy stock poised for growth - Investing.com Nigeria
Artiva Biotherapeutics (NASDAQ:ARTV) Now Covered by HC Wainwright - MarketBeat
This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Franklin Resources Inc. Purchases Shares of 520,301 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat
Nk Cell Therapy Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Artiva Biotherapeutics, Dragonfly therapeutics, Affimed, XNK Therapeut - Barchart
Nk Cell Therapy Pipeline 2024: Clinical Trials Assessment, FDA - openPR
BNP Paribas Financial Markets Invests $42,000 in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Charles Schwab Investment Management Inc. Invests $623,000 in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Wellington Management Group LLP Makes New Investment in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat
Artiva Biotherapeutics's SWOT analysis: NK cell therapy stock poised for autoimmune breakthrough - Investing.com India
After Making the IPO Jump, Biotechs Landed On a Slippery Slope - BioSpace
RA Capital Management L.P. Purchases Shares of 9,853,302 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat
291,666 Shares in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Purchased by Samsara BioCapital LLC - MarketBeat
RTW Investments LP Invests $2.30 Million in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat
Acuta Capital Partners LLC Purchases Shares of 44,000 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat
Artiva Biotherapeutics Inc Stock (ARTV) Financials Data
There is no financial data for Artiva Biotherapeutics Inc (ARTV). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Artiva Biotherapeutics Inc Stock (ARTV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| 5AM Partners VI, LLC | 10% Owner |
Jul 22 '24 |
Buy |
12.00 |
833,333 |
9,999,996 |
1,182,054 |
| venBio Global Strategic Fund I | 10% Owner |
Jul 22 '24 |
Buy |
12.00 |
416,666 |
4,999,992 |
1,936,637 |
| GC Corp. | 10% Owner |
Jul 22 '24 |
Buy |
12.00 |
1,666,666 |
19,999,992 |
3,306,900 |
| GC Corp. | 10% Owner |
Jul 22 '24 |
Buy |
12.00 |
416,666 |
4,999,992 |
1,260,512 |
| Huh Yong-Jun | Director |
Jul 22 '24 |
Buy |
12.00 |
2,083,332 |
24,999,984 |
3,306,900 |
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):